Basilea Pharmaceutica AG | Mutual Funds
Mutual Funds that own Basilea Pharmaceutica AG
Black Creek International Equity Fund
231,222
1.95%
-84,862
1.47%
06/30/2017
Vanguard Total International Stock Index Fund
154,701
1.3%
0
0%
07/31/2018
United Financial-International Equity Alpha Corporate Class
124,984
1.05%
-51,235
1.61%
06/30/2017
Black Creek Global Balanced Fund
111,000
0.93%
-107,000
0.8%
06/30/2017
Government Pension Fund - Global (The)
90,381
0.76%
54,354
0%
12/31/2017
CSIF Switzerland Total Market Index
70,406
0.59%
-798
0.05%
05/31/2018
Black Creek Global Balanced Corporate Class
70,000
0.59%
-65,000
0.81%
06/30/2017
iShares Core MSCI EAFE ETF
66,871
0.56%
0
0.01%
09/06/2018
Vanguard Developed Markets Index Fund
62,006
0.52%
0
0%
07/31/2018
iShares MSCI EAFE Small Cap ETF
61,406
0.52%
0
0.04%
09/06/2018
| Address |
Grenzacherstrasse 487
Basel Basel-Stadt (Basle Town) 4058
Switzerland
|
|
Employees
|
- |
| Website |
http://www.basilea.com |
| Updated |
07/08/2019 |
| Basilea Pharmaceutica AG is a biopharmaceutical company, with focus on bacterial infections, fungal infections and cancer. The company engages in the discovery, development, and commercialization of pharmaceutical products. Its products include Cresemba Isavuconazole, Zevtera/Mabelio Ceftobiprole, Toctino, and Microbiology Test. |
